Levetiracetam Solution
Product Images NDC 72162-2639

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72162-2639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622639)

This text provides instructions for the usage and storage of the medication Levetiracetam oral solution. It includes details such as the recommended dosage, storage temperature, and cautions to keep the medication out of reach of children. The text also instructs pharmacists to dispense the medication in child-resistant packaging and to provide the Medication Guide separately to each patient. The manufacturer and relabeling information for the medication are also included.*

FDA Label Image

Levetiracetam-figure-1 (Levetiracetam Figure 1)

This text provides information about a study involving placebo and different dosages of levetiracetam (1000 mg/day and 3000 mg/day) with varying sample sizes for each group. The study appears to have included 95 individuals in the placebo group, 97 individuals in the 1000 mg/day levetiracetam group, and 101 individuals in the 3000 mg/day levetiracetam group.*

FDA Label Image

Levetiracetam-figure-2 (Levetiracetam Figure 2)

This text shows a comparison between a placebo group (N=111) and two different dosages of Levetiracetam (1000 mg/day for N=106 and 2000 mg/day for N=105). The percentages indicate the frequency of occurrence of certain values or responses in each group. The data suggests the effectiveness of Levetiracetam at different dosages compared to a placebo in the study.*

FDA Label Image

Levetiracetam-figure-3 (Levetiracetam Figure 3)

This text provides information on the distribution of participants within a study evaluating the effectiveness of Levetiracetam compared to a placebo. The study includes 104 participants in the placebo group and 180 participants receiving 3000 mg/day of Levetiracetam. The numbers show the percentage of participants in each group, with 14.4% in the placebo group and 39.4% in the Levetiracetam group.*

FDA Label Image

Levetiracetam-figure-4 (Levetiracetam Figure 4)

This text provides information about the percentage of patients in a study who received a placebo (19.6%, N=97) compared to those who received levetiracetam (44.6%, N=101). This data may be helpful in understanding the distribution of treatments in the study.*

FDA Label Image

Levetiracetam-figure-5 (Levetiracetam Figure 5)

This text shows data on the percentage of 45% for the placebo group and 43.1% for the Levetiracetam group, with sample sizes (N) of 51 for the placebo and 58 for the Levetiracetam group. This data may be part of a clinical trial or study comparing the effects of these treatments.*

FDA Label Image

Levetiracetam-figure-6 (Levetiracetam Figure 6)

FDA Label Image

Levetiracetam-structure (Levetiracetam Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.